These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 29932416)
1. Bioequivalence assessment of tulobuterol transdermal delivery system in healthy subjects . Park SI; Kim BH Int J Clin Pharmacol Ther; 2018 Aug; 56(8):381-386. PubMed ID: 29932416 [TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration. Kim JH; Kim TH; Park HJ; Choi YJ; Kang JH; Song KH; Koo TS; Seo KW Vet J; 2016 Feb; 208():90-2. PubMed ID: 26639828 [TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets in healthy male subjects . Lee H; Yim SV; Kim BH; Lee S Int J Clin Pharmacol Ther; 2017 Jan; 55(1):95-101. PubMed ID: 27841153 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects. Liu Y; Tomlinson B; Guo J; Asgharnejad M; Bauer L; Surmann E; Guo X; Elshoff JP Clin Ther; 2018 Jul; 40(7):1108-1121.e8. PubMed ID: 30098648 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study. Choi HG; Jeon JY; Im YJ; Kim Y; Jang H; Kang S; Kim KH; Chae SW; Lee SY; Kim MG Int J Clin Pharmacol Ther; 2014 Jan; 52(1):55-63. PubMed ID: 24290415 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects . Yoon S; Lee S; Yu KS; Yim SV; Kim BH Int J Clin Pharmacol Ther; 2017 Feb; 55(2):194-200. PubMed ID: 27879195 [TBL] [Abstract][Full Text] [Related]
7. Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. Yamagata T; Hirano T; Sugiura H; Yanagisawa S; Ichikawa T; Ueshima K; Akamatsu K; Nakanishi M; Matsunaga K; Minakata Y; Ichinose M Pulm Pharmacol Ther; 2008; 21(1):160-5. PubMed ID: 17632023 [TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Uematsu T; Nakano M; Kosuge K; Kanamaru M; Nakashima M Eur J Clin Pharmacol; 1993; 44(4):361-4. PubMed ID: 8099880 [TBL] [Abstract][Full Text] [Related]
9. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men. Wilson DE; Meikle AW; Boike SC; Fairless AJ; Etheredge RC; Jorkasky DK J Clin Pharmacol; 1998 Jan; 38(1):54-9. PubMed ID: 9597560 [TBL] [Abstract][Full Text] [Related]
10. Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study. Almeida S; Pedroso P; Filipe A; Pinho C; Neves R; Jiménez C; Sicard E; Lefebvre M Arzneimittelforschung; 2011; 61(3):153-9. PubMed ID: 21528639 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men. Choi HK; Ghim JL; Shon J; Choi YK; Jung JA Drug Des Devel Ther; 2016; 10():3493-3499. PubMed ID: 27822013 [TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers. Lorch U; Pierscionek T; Freier A; Spencer CS; Täubel J Clin Pharmacol Drug Dev; 2021 Mar; 10(3):260-271. PubMed ID: 32748570 [TBL] [Abstract][Full Text] [Related]
13. Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. Liu J; Zhou X Int J Clin Pharmacol Ther; 2014 Feb; 52(2):175-80. PubMed ID: 24424109 [TBL] [Abstract][Full Text] [Related]
14. [Model analysis of tulobuterol patch formulations to explain the influence of drug release rate and transdermal transfer rate on the plasma concentration profile]. Watanabe T; Satoh H; Hori S; Miki A; Ohtani H; Sawada Y Yakugaku Zasshi; 2011; 131(10):1483-92. PubMed ID: 21963976 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. Choi Y; Han H; Shin D; Lim KS; Yu KS Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511 [TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of two intravenous formulations of antithrombin III: a two-way crossover study in healthy Korean subjects. Kim KA; Lim YY; Kim SH; Park JY Clin Ther; 2013 Nov; 35(11):1752-61. PubMed ID: 24094463 [TBL] [Abstract][Full Text] [Related]
17. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers. Weisfeld L; Shu Y; Shah TP Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485 [TBL] [Abstract][Full Text] [Related]
18. Transdermal tulobuterol patch, a long-actingβ(2)-agonist. Tamura G; Ichinose M; Fukuchi Y; Miyamoto T Allergol Int; 2012 Jun; 61(2):219-29. PubMed ID: 22270072 [TBL] [Abstract][Full Text] [Related]
19. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects. Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778 [TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life. Sanga M; Vaughan S; Nangosyah J; Scholz V; Fonseca S Int J Clin Pharmacol Ther; 2022 Jan; 60(1):67-78. PubMed ID: 34779392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]